Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro.
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Antineoplastic Agents, Immunological
/ pharmacology
Antineoplastic Agents, Phytogenic
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Squamous Cell
/ drug therapy
Cell Proliferation
Cetuximab
/ pharmacology
Drug Synergism
Humans
In Vitro Techniques
Mouth Neoplasms
/ drug therapy
Paclitaxel
/ pharmacology
Tumor Cells, Cultured
antibody-dependent cellular cytotoxicity (ADCC)
cetuximab
epidermal growth factor receptor (EGFR)
oral squamous cell carcinoma (OSCC)
paclitaxel
synergistic effects
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Aug 2020
31 Aug 2020
Historique:
received:
31
07
2020
revised:
27
08
2020
accepted:
28
08
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
20
2
2021
Statut:
epublish
Résumé
Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells.
Identifiants
pubmed: 32878053
pii: ijms21176292
doi: 10.3390/ijms21176292
pmc: PMC7503545
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Antineoplastic Agents, Phytogenic
0
Paclitaxel
P88XT4IS4D
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Dokkyo Medical University, Young Investigator Award
ID : No.2018-14
Références
Anticancer Res. 2019 Mar;39(3):1275-1282
pubmed: 30842158
Cell Cycle. 2016 Dec;15(23):3268-3277
pubmed: 27764550
Anticancer Res. 2007 Sep-Oct;27(5A):3355-66
pubmed: 17970081
Cancer Res. 1999 Aug 15;59(16):4142-7
pubmed: 10463620
Clin Cancer Res. 2007 Nov 1;13(21):6419-28
pubmed: 17962339
PLoS One. 2015 Feb 06;10(2):e0117781
pubmed: 25658924
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Oral Oncol. 2003 Feb;39(2):115-29
pubmed: 12509964
Oral Oncol. 2016 Feb;53:10-6
pubmed: 26712252
Clin Cancer Res. 2016 Nov 1;22(21):5229-5237
pubmed: 27217441
Oncogene. 2010 Sep 16;29(37):5135-45
pubmed: 20622897
Int J Cancer. 2001 Aug 15;93(4):489-96
pubmed: 11477552
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
N Engl J Med. 1993 Jan 21;328(3):184-94
pubmed: 8417385
Cancer Res. 1986 Apr;46(4 Pt 1):1648-53
pubmed: 3004701
Ann Oncol. 2012 Apr;23(4):1016-22
pubmed: 21865152
Int J Oncol. 1999 Oct;15(4):661-7
pubmed: 10493946
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Cancer Lett. 2000 Dec 8;161(1):9-15
pubmed: 11078908
JAMA Oncol. 2020 Jul 1;6(7):1068-1071
pubmed: 32407439
Int J Cancer. 1993 Dec 2;55(6):968-73
pubmed: 8253534